cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Foghorn Therapeutics Inc
4 own
2 watching
Current Price
$0
$0.07
(0.86%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
338.78M
52-Week High
52-Week High
18.12
52-Week Low
52-Week Low
4.51
Average Volume
Average Volume
0M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization338.78M
icon52-Week High18.12
icon52-Week Low4.51
iconAverage Volume0M
iconDividend Yield--
iconP/E Ratio--
What does the Foghorn Therapeutics Inc do?
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Foghorn Therapeutics Inc make?
News & Events about Foghorn Therapeutics Inc.
PR Newswire
1month ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX PR Newswire NEW YORK, May 2, 2023 NEW YORK, May 2, 2023...
PR Newswire
1month ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX PR Newswire NEW YORK, April 26, 2023 NEW YORK, April 26, 2023...
Globe Newswire
3 months ago
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will participate at Cowens 43rd Annual...
Globe Newswire
5 months ago
- Phase 1 dose escalation study of FHD-286, a BRG1/BRM inhibitor, in metastatic uveal melanoma continues to progress with initial efficacy and safety data expected in the first half of 2023 - Phase 1 dose escalation study of FHD-609, a selective degrader of BRD9, in synovial sarcoma continues to ...
Ticker Report
5 months ago
Research analysts at BMO Capital Markets began coverage on shares of Foghorn Therapeutics (NASDAQ:FHTX Get Rating) in a research report issued on Thursday, The Fly reports. The brokerage set an outperform rating and a $20.00 price target on the stock. BMO Capital Markets&#8217...
Frequently Asked Questions
Frequently Asked Questions
What is Foghorn Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Foghorn Therapeutics Inc shares?
plus_minus_icon
How can I buy Foghorn Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Foghorn Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Foghorn Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Foghorn Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Foghorn Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Foghorn Therapeutics Inc?
plus_minus_icon
What percentage is Foghorn Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Foghorn Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.07
(0.86%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
TARSUS PHARMACEUTICALS INC
TARSUS PHARMACEUTICALS INC
$19.00
$-0.63 (-3.21 %)
POSEIDA THERAPEUTICS INC
POSEIDA THERAPEUTICS INC
$2.35
$0.04 (1.73 %)
PMV PHARMACEUTICALS INC
PMV PHARMACEUTICALS INC
$5.58
$-0.01 (-0.18 %)
Athira Pharma Inc
Athira Pharma Inc
$3.43
$-0.08 (-2.28 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
TARSUS PHARMACEUTICALS INC
TARSUS PHARMACEUTICALS INC
$19.00
$-0.63 (-3.21 %)
POSEIDA THERAPEUTICS INC
POSEIDA THERAPEUTICS INC
$2.35
$0.04 (1.73 %)
PMV PHARMACEUTICALS INC
PMV PHARMACEUTICALS INC
$5.58
$-0.01 (-0.18 %)
Athira Pharma Inc
Athira Pharma Inc
$3.43
$-0.08 (-2.28 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00